
    
      The objective of this study is to evaluate the safety, efficacy, and pharmacokinetics of
      MGAWN1 in subjects with West Nile Fever or a syndrome compatible with West Nile Neuroinvasive
      Disease (WNND) [encephalitis, meningitis, or acute flaccid paralysis]. Subjects can be
      enrolled based on a syndrome compatible with WNND, and do not need documented West Nile virus
      infection.
    
  